Navigation Links
BUSM researchers part of multi-center study on cardiac amyloidosis
Date:8/13/2012

(Boston) - Researchers at Boston University School of Medicine (BUSM) have been part of a multicenter observational study called TRACS (Transthyretin Amyloidosis Cardiac Study) to help determine the health significance of a particular gene mutation which is commonly found in Black Americans.

The gene, transthyretin (TTR) and the mutation V122I, is seen in about four percent of African Americans or roughly 1.5 million people. The mutation is strongly associated with a condition called cardiac amyloidosis - a disorder where the abnormally mutated TTR protein deposits in the heart of affected individuals, causing the heart to not pump adequately and ultimately results in death. Cardiac amyloidosis due to this mutation is seen in older people, over the age of 60 years. Cardiac amyloidosis can be also be due to genetically normal TTR as well, which occurs for unclear reasons but is strongly associated with age and male gender.

The researchers enrolled 29 patients with TTR cardiac amyloidosis due to either the V122I mutation or those with genetically normal TTR, and observed them for roughly 16 months. They found that Black patients with the mutation only survived for a median of 26 months after diagnosis, and that certain measured parameters including heart function by echocardiography, blood testing and exercise capacity fell during the study and were associated with survival. Quality of life determined by questionnaire also declined significantly. These findings currently appear online in the American Heart Journal.

"This study is important because it establishes that carriers of V122I are at increased risk of death from cardiac amyloidosis once they reach an age where the disease is expressed (generally over the age of 60)," explained lead author Frederick L. Ruberg, MD, assistant professor of medicine and radiology at BUSM. According to Ruberg these findings provide an important foundation on which future studies using new drugs
'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. BUSM/VA researchers uncover gender differences in the effects of long-term alcoholism
2. Excellence Initiative winner TU München invests in the future: Young researchers
3. Clemson researchers collect and reuse enzymes while maintaining bioactivity
4. Healthcare researchers recognized at SingHealth Duke-NUS Scientific Congress 2012
5. Northwestern researchers investigate treatment for tumor cells in spinal fluid
6. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
7. MDC researchers develop new approach to treat acute liver failure
8. Breast Cancer Charity Overstates Value of Mammograms: Researchers
9. Boston University researchers expand synthetic biologys toolkit
10. Global health researchers urge integrating de-worming into HIV care in Africa
11. Researchers find potential cancer roadblock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 As obesity rates sky ... need for surgical equipment during childbirth comes as no shock. ... within the mother when she is unable to do so ... are associated with higher rates of complication for both the ... harmful to the mother and child, forceps births add to ...
(Date:6/18/2013)... WA (PRWEB) June 18, 2013 SEATTLE, ... Townsend Farms of Fairview, Oregon, claiming he fell ill ... frozen berry and pomegranate seed blend. The complaint ... 13-2-05597-8) by Marler Clark, the Seattle-based law firm that ... .[1] , According to the complaint, Brian Brothers consumed ...
(Date:6/18/2013)... The Drug Delivery Partnering Terms and Agreements ... drug delivery partnering deals and agreements entered into by ... provides a detailed understanding and analysis of how and ... of deals are discovery or development stage whereby the ... license the license drug delivery technology. These deals tend ...
(Date:6/18/2013)... The Temp1000IS temperature data logger ... can be used to automatically record temperatures between -20 ... Temp1000IS comes with the serial number and device name ... (sold separately) docking station and can be placed directly ... removal of end-caps to download data. The small size ...
(Date:6/18/2013)... Parker Waichman LLP , a ... victims injured by defective medical devices, reports that the ... bone graft products are now available. Published this week ... two studies serve up two key findings: There is ... and the traditional bone graft; and there is “substantial ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3
... Reinberg HealthDay Reporter , WEDNESDAY, May 25 ... a "polypill," appears to cut users, odds for heart ... study finds. The pill combines two blood pressure-lowering ... designed to make all these heart-protecting drugs easy to ...
... 25, 2011) The cost of cancer care is threatening ... but at staggering costs. This coupled with aging baby boomers ... billion annually on cancer care by the year 2020. This ... maintain or improve the quality of care while saving money ...
... CA (May 26, 2011) Precision tinted lenses have ... poor readers, and are increasingly used for migraine sufferers, ... been unclear. Now research published in the journal ... imaging (fMRI) for the first time to suggest a ...
... NY, May 26, 2011Young adults ages 19-29 are struggling to ... other age group, demonstrating the need for Affordable Care Act ... and make it more affordable, according to a new Commonwealth ... of young adults couldn,t afford the care they needed, meaning ...
... 2011 UT Southwestern Medical Center researchers are engaging the ... component in red wine and grapes could help reduce the ... recruit about two dozen professional boxers to take the neuroprotective ... damage to the brain after impact and helps restore subtle ...
... bats and dolphins echolocate, emitting bursts of sounds and then ... What is less well-known is that people can echolocate too. ... make clicks with their mouths and to use the returning ... these individuals are so adept at echolocation that they can ...
Cached Medicine News:Health News:Daily Four-Drug Combo Pill Halves Heart Disease Risk: Study 2Health News:Daily Four-Drug Combo Pill Halves Heart Disease Risk: Study 3Health News:Oncologists hold key to curbing cancer costs 2Health News:Oncologists hold key to curbing cancer costs 3Health News:Tinted specs offer real migraine relief, says fMRI study 2Health News:Tinted specs offer real migraine relief, says fMRI study 3Health News:Health reform essential to young adults: Nearly half can't afford needed health care 2Health News:Health reform essential to young adults: Nearly half can't afford needed health care 3Health News:Health reform essential to young adults: Nearly half can't afford needed health care 4Health News:Researchers evaluate red wine compound for treating concussions in pro boxers 2Health News:'I can hear a building over there' 2
(Date:6/18/2013)... June 18, 2013 Valeant Pharmaceuticals International, Inc. ... "Company") announced today that VPII Escrow Corp., a newly ... launched its offer of approximately $3.2 billion aggregate principal ... will be due in 2021 and in 2023, with ... intends to use the net proceeds from the offering, ...
(Date:6/18/2013)... YORK , June 18, 2013  Intercept Pharmaceuticals, ... biopharmaceutical company focused on the development and commercialization of ... today announced the pricing of an underwritten public offering ... public offering price of $33.01 per share.  In addition, ... purchase up to an additional 259,500 shares of common ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals ... VRX) has priced its previously announced public offering of ... Company will issue 23,529,412 common shares at a price ... approximately $2.0 billion. The Company will file a final ... Form S-3 and will make a similar filing with ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... announced that data,presented recently at the 17th Annual ... that the Genous Bio-engineered R,stent has better outcomes ... Federico Piscione, M.D., the study,s principal,investigator and a ... of Cardiology, Department of Clinical Medicine and Cardiovascular,Sciences, ...
... Results are basis for CTI,s Marketing Authorization Application currently ... under ... Inc. (CTI),(Nasdaq: CTIC ; MTA) today announced the publication of ... gemcitabine or vinorelbine for the treatment of PS 2,(performance status 2) ...
Cached Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The BD Vacutainer® One Use Holder is a quality, low-cost single use holder that can help customers comply with OSHA regulations (Safety and Health Information Bulletin 10-15-03)...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Inquire...
Medicine Products: